Neurogene Inc. unveils corporate presentation highlighting gene therapy advances for Rett syndrome and rare neurological diseases

Neurogene Inc. has released a corporate presentation detailing updates on its clinical pipeline for rare neurological diseases. The company’s lead program, NGN-401 for Rett syndrome, has demonstrated promising interim clinical data, with the Embolden registrational trial currently ongoing. Enrollment for the trial is expected to complete within the next three to six months. NGN-401 leverages Neurogene’s proprietary EXACT transgene regulation technology, which is designed to deliver consistent and tightly controlled MeCP2 protein expression on a cell-by-cell basis. The company also highlighted its internal manufacturing capabilities, including a 42,000 square foot facility in Houston, which supports both current and future clinical and commercial production needs. Additional pipeline updates include NGN-101 for CLN5 Batten Disease, with further interim data expected in 2026. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here